Furthermore, studies have shown that treatment with PPARγ agonists, rosiglitazone and troglitazone, or conversely with PPARγ antagonists, GW9662 and T0070907, were both found to significantly inhibit the growth of a wide variety of cancer cell lines [40, 41]. This evidence concerns the gene PPARG and cancer.